Search Results - "Niu, Mengke"

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions by Yi, Ming, Zheng, Xiaoli, Niu, Mengke, Zhu, Shuangli, Ge, Hong, Wu, Kongming

“…Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer…”
Get full text

Regulation of PD-L1 expression in the tumor microenvironment by Yi, Ming, Niu, Mengke, Xu, Linping, Luo, Suxia, Wu, Kongming

“…Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For…”
Get full text

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy by Wu, Yuze, Yi, Ming, Niu, Mengke, Mei, Qi, Wu, Kongming

“…Abstract The clinical responses observed following treatment with immune checkpoint inhibitors (ICIs) support immunotherapy as a potential anticancer…”
Get full text

CD44 as a tumor biomarker and therapeutic target by Xu, Hanxiao, Niu, Mengke, Yuan, Xun, Wu, Kongming, Liu, Aiguo

“…CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44…”
Get full text

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer by Niu, Mengke, Liu, Yiming, Yi, Ming, Jiao, Dechao, Wu, Kongming

“…The immune checkpoint pathway consisting of the cell membrane-bound molecule programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate…”
Get full text

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 by Yi, Ming, Zhang, Jing, Li, Anping, Niu, Mengke, Yan, Yongxiang, Jiao, Ying, Luo, Suxia, Zhou, Pengfei, Wu, Kongming

“…Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses…”
Get full text

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers by Yi, Ming, Niu, Mengke, Zhang, Jing, Li, Shiyu, Zhu, Shuangli, Yan, Yongxiang, Li, Ning, Zhou, Pengfei, Chu, Qian, Wu, Kongming

“…Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models…”
Get full text

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy by Yi, Ming, Li, Tianye, Niu, Mengke, Wu, Yuze, Zhao, Zhenyu, Wu, Kongming

“…Transforming growth factor-β (TGF-β) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and…”
Get full text

Exploiting innate immunity for cancer immunotherapy by Yi, Ming, Li, Tianye, Niu, Mengke, Mei, Qi, Zhao, Bin, Chu, Qian, Dai, Zhijun, Wu, Kongming

“…Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing…”
Get full text

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC by Niu, Mengke, Yi, Ming, Li, Ning, Luo, Suxia, Wu, Kongming

“…Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of…”
Get full text

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors by Yi, Ming, Niu, Mengke, Wu, Yuze, Ge, Hong, Jiao, Dechao, Zhu, Shuangli, Zhang, Jing, Yan, Yongxiang, Zhou, Pengfei, Chu, Qian, Wu, Kongming

“…Abstract Background Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy…”
Get full text

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer by Yi, Ming, Wu, Yuze, Niu, Mengke, Zhu, Shuangli, Zhang, Jing, Yan, Yongxiang, Zhou, Pengfei, Dai, Zhijun, Wu, Kongming

“…BackgroundAgents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC)…”
Get full text

Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study by Yi, Ming, Li, Tianye, Niu, Mengke, Luo, Suxia, Chu, Qian, Wu, Kongming

“…Abstract Background Every year around the world, more than 2 million women are diagnosed with breast cancer and genital tract cancers. However, there are rare…”
Get full text

Advances of Targeted Therapy for Hepatocellular Carcinoma by Niu, Mengke, Yi, Ming, Li, Ning, Wu, Kongju, Wu, Kongming

“…Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which is a significant global health problem. The clinical applicability of…”
Get full text

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy by Li, Tianye, Wang, Xinrun, Niu, Mengke, Wang, Mingli, Zhou, Jianwei, Wu, Kongming, Yi, Ming

“…The PD-1/PD-L1 signaling pathway plays a crucial role in cancer immune evasion, and the use of anti-PD-1/PD-L1 antibodies represents a significant milestone in…”
Get full text

CAR-NK cells for cancer immunotherapy: recent advances and future directions by Li, Tianye, Niu, Mengke, Zhang, Weijiang, Qin, Shuang, Zhou, Jianwei, Yi, Ming

“…Natural Killer (NK) cells, intrinsic to the innate immune system, are pivotal in combating cancer due to their independent cytotoxic capabilities in antitumor…”
Get full text

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling by Li, Tianye, Niu, Mengke, Zhou, Jianwei, Wu, Kongming, Yi, Ming

“…The programmed cell death 1 (PD-1) signaling pathway, a key player in immune checkpoint regulation, has become a focal point in cancer immunotherapy. In the…”
Get full text

STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance by Li, Tianye, Zhang, Weijiang, Niu, Mengke, Wu, Yuze, Deng, Xinyue, Zhou, Jianwei

“…Cervical cancer poses a significant global threat to women's health. However, current therapeutic interventions, such as radiotherapy, chemotherapy, surgical…”
Get full text

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy by Niu, Mengke, Yi, Ming, Wu, Yuze, Lyu, Lijuan, He, Qing, Yang, Rui, Zeng, Liang, Shi, Jian, Zhang, Jing, Zhou, Pengfei, Zhang, Tingting, Mei, Qi, Chu, Qian, Wu, Kongming

“…Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors…”
Get full text

Influence of He injection amount on the microstructure of ion irradiated Cr0.8FeMnNi medium entropy alloy compared with 316L stainless steel by Niu, Mengke, Hashimoto, Naoyuki, Oka, Hiroshi, Sun, Haotian

“…•Different He amounts were injected into MEA and 316L to investigate He effect.•Irradiation defects in no He injected MEA has smaller size and higher number…”
Get full text